Figure 2
Blood concentration of itraconazole (ITCZ) and hydroxyitraconazole (ITCZ-OH).
tration were achieved without any significant side-effects. Serum level of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were within the normal range during 900 mg/day ITCZ administration. The patient's fever and low back pain decreased and the serum ␤-D-glucan level became normal. Thus, from these results, we suggest that the oral administration of ITCZ at a high dose is clinically useful to treat a case of Aspergillus spondylodiscitis.
Aspergillus spondylodiscitis is one of the rare complications of the deep mycotic infections. 1 In cases of hematological disorder, surgical debridement of the fungus abscess on the lumbar disc is usually not indicated because of the patient's poor systemic condition due to malignant disease. Although AMPH has been predominantly used as the first choice of drug for such patients, 2 it has been reported that intravenous AMPH therapy has a low success rate (34%) against invasive aspergillosis. 3 Moreover, if the patient does not respond to a high dose of AMPH, or if the side-effects are severe, it is difficult to exchange AMPH for other drugs. In the present case, the administration of a high dose of ITCZ was effective without any serious sideeffects. Glasmacher et al 4 In a recent paper published in Leukemia, Tabernero et al 3 identified a unique immunophenotype expressed by adult precursor B lineage acute lymphoblastic leukaemia with BCR-ABL rearrangement. This finding is based on the analysis of surface antigens, such as the homogeneous expression of CD10 and CD34, heterogeneous or low expression of CD38 and aberrant CD13. In our experience, we have also found that BCR-ABL-positive ALL, can also display cytoplasmic Leukemia least 500 ng/ml ITCZ was necessary for an effective antifungal prophylaxis in neutropenic patients and they compared the results of drug monitoring in patients with acute leukemia receiving six different dosing regimens using ITCZ capsules and hydroxypropyl-␤-cyclodexytrin solution in their clinical study. They concluded that the maximum dosing group, 400 mg/day ITCZ solution with a loading dose of 800 mg/day capsules for 7 days resulted in sufficient trough concentrations for significant antifungal prophylaxis in neutropenic patients. To our knowledge, this is the first reported case of ITCZ therapy administered at such a high dose as 900 mg/day as capsules only, without complications. Though future studies are needed to elucidate the efficacy and toxicity of high-dose ITCZ therapy, it could be the appropriate substitute of AMPH-resistant invasive aspergillosis. immunophenotyping of 45 ALL (T-lineage n = 10, B-lineage: n = 35, mean age: 24.7 years, range: 2-47). Out of these, seven cases displayed chromosomal translocation t(9;22)(q34;q11.2) by conventional cytogenetic study or BCR-ABL fusion transcripts detected by RT-PCR (T-lineage n = 2, B-lineage n = 5, mean age: 24.7 years, range: 3-41). All these cases were MPO negative by standard cytochemical staining and were unequivocally B-or T-lineage ALL based on morphological, cytochemical and immunophenotypic criteria using monoclonal antibodies (MnAbs) anti-cytoplasmic CD79 or CD3, respectively. Using a FITC-conjugated MnAb against MPO (Clone MPO-7, Dako, Denmark), we analysed the expression specifically in blast ALL cells by multiparametric flow cytometry, using a dual laser FACScalibur flow cytometer (Becton Dickinson, Mountain View, CA, USA) and the following MnAbs: CD19 (Clone HD37-PE), CD3 (clone UCHT-1-PE) both from Dako (Glostrup, Denmark), and CD10 (clone Hl10a-APC), CD34 (Clone HPCA2-PerCP) both from Becton Dickinson. Intracellular MPO was detected using two permeabilisation commercial reagents (OrthoPemeafix; Ortho, Raritan, NJ, USA and DAKO IntraStain; Dako). Specificity of this MPO MnAb was tested using mononuclear peripheral blood cells from healthy donors and patients suffering from chronic lymphoid leukaemia, mononuclear bone marrow cells obtained from healthy donors and from AML at diagnosis. The latter displayed strong positivity but no reactivity or only a certain degree of non-specific binding was observed in lymphoid gate in the other samples. No MPO reactivity or less than 5% was noted in all cases of ALL without BCR-ABL rearrangements. By contrast, three (one The expression of MPO precursor protein detected by FCM in otherwise well-defined ALL, has been previously reported. 4 Our results, confirmed by two different permeabilisation methods, demonstrate that MPO positivity in ALL is not related to artefact or misinterpretation and could be highly suggestive of underlying BCR-ABL rearrangements, regardless of the LAL lineage (B or T). The high incidence of this finding in ALL cases bearing BCR-ABL further reinforces that these acute leukaemias arise from a pluripotent stem cell precursor Ph+ capable of differentiating to myeloid or lymphoid lineage. 5, 6 Whether these MPO-positive ALL detected only by flow cytometry should be classified as biphenotypic leukaemias according to the scoring systems, could be a matter of debate. Additionally, this MPO expression could be used as an additional marker for minimal residual disease (MRD) monitoring. However, standardisation of analysis of intracellular antigens by FCM is needed in order to improve comparability of results for reliable lineage-assignment and its usefulness as a MRD marker.
